Abstract
Purpose of Review
The purpose of this paper is to review the development and clinical evaluation of AltaSeal® which is being developed as an easy-to-use hysteroscopic sterilization implant. The implant made from 316 LVM bio-compatible stainless steel has been tested in clinical trials both for its efficacy in preventing pregnancy and its ability to occlude fallopian tubes with hydrosalpinges ahead of in vitro fertilization (IVF) therapies.
Recent Findings
The clinical data to date suggests that when placed correctly, AltaSeal® can effectively prevent pregnancy. In an observational study of patients with hydrosalpinges, AltaSeal® data suggests that the fallopian tubes are effectively closed by the AltaSeal® implants, thereby increasing IVF efficacy.
Summary
The results to date suggest that AltaSeal® can efficiently occlude fallopian tubes for both the prevention of pregnancy and possibly return the success rate of IVF in patients with hydrosalpinges to levels seen in patients without hydrosalpinges. Further clinical studies are ongoing to expand the clinical data.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Jones J, Mosher W, Daniels K. National Health Statistics Report: Current contraceptive use in the United States, 2006–2010, and changes in patterns of use since 1995 [Internet]. U.S. Washington (USA): Department of Health and Human Services; 2012 [cited 2016 April 26]. Report No: 60. Available from: http://www.cdc.gov/nchs/data/nhsr/nhsr060.pdf.
Micks E, Jensen J. Permanent contraception for women. Women’s Health. 2015;11(6):769–77. doi:10.2217/whe.15.69.
Jamieson D, Hillis S, Duerr A. Complications of interval laparoscopic tubal sterilization: findings from the United States collaborative review of sterilization. Obstet Gynecol. 2000;96(6):997.
Patil EJensen J. Update on permanent contraception options for women. Curr Opin Obstet Gynecol. 2015;27(6):465–70. doi:10.1097/GCO.0000000000000213.
American College of Obstetricians and Gynecologists. Practice bulletin no. 133: benefits and risks of sterilization. Obstetrics Gynecology. 2013;121(2):392–404. doi:10.1097/01.AOG.0000426425.33845.b2.
la Chapelle C, Veersema S, Brölmann H, Jansen F. Effectiveness and feasibility of hysteroscopic sterilization techniques: a systematic review and meta-analysis. Fertil Steril. 2015;103(6):1516–1525.e3. doi:10.1016/j.fertnstert.2015.03.009.
Chudnoff S, Nichols J, Levie M. Hysteroscopic essure inserts for permanent contraception: extended follow-up results of a phase III multicenter international study. J Minim Invasive Gynecol. 2015;22(6):951–60. doi:10.1016/j.jmig.2015.04.017.
Valle R, Carignan C, Wright T. Tissue response to the STOP microcoil transcervical permanent contraceptive device: results from a prehysterectomy study. Fertil Steril. 2001;76(5):974–80.
Anderson T, Vancaillie T. The Adiana System for permanent contraception: safety and efficacy at 3 years. J Minim Invasive Gynecol. 2011;18(5):612–6. doi:10.1016/j.jmig.2011.06.002.
Coolen A, Bongers M, Thurkow A, Emanuel M, Timmerman E, Ruhe I, et al. Success rate of the Adiana® hysteroscopic sterilization technique. J Minim Invasive Gynecol. 2011;18(6):S18–9. doi:10.1016/j.jmig.2011.08.072.
U.S. Food and Drug Administration. Update on the status of FDA’s evaluation of the Essure System. [updated 2016 November 15; cited 2015 October 21]. Available from: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsImplant/EssurePermanentBirthControl/ucm473946.htm.
Veersema S. Hysteroscopy and contraception. Best Practice & Research Clinical Obstetrics & Gynaecology. 2015;29(7):940–50. doi:10.1016/j.bpobgyn.2015.03.013.
Maclean C, Thompson I. Postpartum care and contraception in obese women. Clin Obstet Gynecol. 2016;59(1):204–15. doi:10.1097/grf.0000000000000176.
•• Thurkow A. AltaSeal hysteroscopic sterilization: the new challenger to Essure? J Minim Invasive Gynecol. 2011;18(6):S38. doi:10.1016/j.jmig.2011.08.133. This highlights AltaSeal® results.
•• Gannon M. I122 first clinical results of new hysteroscopic sterilization device: Altaseal. Int J Gynecol Obstet. 2012;119:S190. doi:10.1016/s0020-7292(12)60152-0. This highlights AltaSeal® results.
Lawrie T, Kulier R, Nardin J. Techniques for the interruption of tubal patency for female sterilization. Cochrane Database Syst Rev. 2016;8. doi: 10.1002/14651858.CD003034.
• Santonen T, Stockmann-Juvala H, Zitting A. Review on toxicity of stainless steel. 1st ed. Finnish Institute of Occupational Health; 2010. This paper highlights the biocompatible nature of 316 LVM stainless steel from which AltaSeal® is made.
Erdmann N, Bondarenko A, Hewicker-Trautwein M, Angrisani N, Reifenrath J, Lucas A, et al. Evaluation of the soft tissue biocompatibility of MgCa0.8 and surgical steel 316L in vivo: a comparative study in rabbits. Biomed Eng Online. 2010;9(1):63. doi:10.1186/1475-925x-9-63.
Raval A, Choubey A, Engineer C, Kothwala D. Development and assessment of 316LVM cardiovascular stents. Mater Sci Eng A. 2004;386(1–2):331–43. doi:10.1016/j.msea.2004.07.051.
Jan A, Crean P, Bullesfeld L, Coleman J, Grube E, Mulvihill N. First clinical experience with Celt ACD ® : a femoral arterial puncture closure device. J Interv Cardiol. 2013;26(4):417–24. doi:10.1111/joic.12046.
Galen D, Khan N, Richter K. Essure multicenter off-label treatment for hydrosalpinx before in vitro fertilization. J Minim Invasive Gynecol. 2011;18(3):338–42. doi:10.1016/j.jmig.2011.01.
Cohen S, Bouaziz J, Schiff E, Simon A, Nadjary M, Goldenberg M, et al. In vitro fertilization outcomes after placement of Essure microinserts in patients with hydrosalpinges who previously failed in vitro fertilization treatment: a multicenter study. J Minim Invasive Gynecol. 2016;23(6):939–43. doi:10.1016/j.jmig.2016.05.010.
•• Gannon M. Hysteroscopic placement of altaseal to occlue hydrosalpinges ahead of IVF in patients contra-indicated for laparoscopic tubal occlusion. Gynecol Surg. 2015;12(1):S64. This highlights AltaSeal® results.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
James E. Coleman declares that he is the Co-Founder and Clinical Director of AltaScience. He also declares patents issued and pending regarding IP on which the technology is based which are owned by JE Coleman.
Marlies Bongers declares that she has no conflicts of interest.
Sebastiaan Veersema declares personal fees from Bayer and Johnson & Johnson for serving as a consultant and/or speaker, and patents pending (Hysteroscopic Shaft—Olympus, and Obstetrical Cutting Instrument—Gynaecologiq).
Andreas Thurkow declares compensation from AltaScience for time invested in the study, which was donated to the department’s scientific foundation, and personal fees as compensation for time invested in advisory board membership and speaker’s fee from Hologic, Johnson & Johnson, Olympus, and Gedeon Richter, and compensation for time invested in expert panel from Bayer.
Michael J. Gannon declares personal fees and non-financial support as aid for clinical time and research nurse from AltaScience and also declares to being a shareholder in AltaScience Ltd.
Due to the nature of this section and the anticipation of bias from the authors as it pertains to this article topic, the article has been reviewed by Dr. James Greenberg of Brigham and Women’s Hospital and by Dr. Mark Levie of Montefiore Medical Center. Both reviewers do not have any conflict of interest with the product reviewed in the article, and they assert that the article is factual and free of excessive bias toward the subject.
Human and Animal Rights and Informed Consent
All patients recruited to trials discussed in this article signed Regulatory Authority and Ethics Committee approved informed consent forms. This article does not contain any studies with animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Emerging and Pipeline Technologies in Ob/Gyn
Rights and permissions
About this article
Cite this article
Coleman, J.E., Bongers, M., Veersema, S. et al. Development and Initial Clinical Experience with AltaSeal®: a Novel Hysteroscopically Placed Permanent Contraception System. Curr Obstet Gynecol Rep 6, 74–81 (2017). https://doi.org/10.1007/s13669-017-0198-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13669-017-0198-y